Literature DB >> 21953808

Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease.

Irune Cariñanos, Manuel Barreiro-De Acosta, Eugeni Domènech.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21953808     DOI： 10.1002/ibd.21723

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  5 in total

1.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

2.  Update in the management of extraintestinal manifestations of inflammatory bowel disease.

Authors:  Seema A Patil; Raymond K Cross
Journal:  Curr Gastroenterol Rep       Date:  2013-03

3.  Pyoderma gangrenosum occurring at the peri-ileal pouch-anal anastomosis in a patient with ulcerative colitis: report of a case.

Authors:  Koji Tanaka; Toshimitsu Araki; Yoshiki Okita; Hiroyuki Fujikawa; Mikio Kawamura; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Surg Today       Date:  2012-12-22       Impact factor: 2.549

4.  Diagnosis and management of parastomal pyoderma gangrenosum.

Authors:  Xian-Rui Wu; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-04-19

Review 5.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.